Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE OTCMKTS:EMIS NASDAQ:OMER NASDAQ:RAPT OTCMKTS:VEGPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.77-5.9%$1.74$1.41▼$5.01$10.40M1.1926,754 shs51,533 shsEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AOMEROmeros$3.46+2.4%$3.73$2.95▼$13.60$198.04M2.16732,079 shs784,232 shsRAPTRapt Therapeutics$8.62+2.1%$7.85$5.67▼$30.60$139.57M-0.09165,065 shs73,324 shsVEGPFVectura Group$1.77$1.77$1.64▼$2.74$1.07B0.372,185 shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-5.85%+1.14%-4.84%+14.19%-55.19%EMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%OMEROmeros+2.37%+8.09%-10.82%-48.59%-14.57%RAPTRapt Therapeutics+2.13%+6.09%-9.45%+24.78%-67.93%VEGPFVectura Group0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics2.559 of 5 stars3.54.00.00.00.00.81.3EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AOMEROmeros3.3055 of 5 stars3.40.00.04.40.01.70.6RAPTRapt Therapeutics4.4177 of 5 stars3.13.00.04.23.21.71.3VEGPFVectura GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50775.71% UpsideEMISEmisphere Technologies 0.00N/AN/AN/AOMEROmeros 2.83Moderate Buy$18.00420.23% UpsideRAPTRapt Therapeutics 2.17Hold$19.80129.70% UpsideVEGPFVectura Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OMER, VEGPF, RAPT, APRE, and EMIS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.006/30/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.006/27/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.006/10/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.005/22/2025RAPTRapt TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.005/22/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$48.005/16/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/13/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.005/7/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/11/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$1.50M6.53N/AN/A$3.55 per share0.50EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/A($3.15) per shareN/ARAPTRapt Therapeutics$1.53M93.19N/AN/A$11.51 per share0.75VEGPFVectura Group$244.76M4.37$0.28 per share6.33$1.16 per share1.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)EMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AOMEROmeros-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)RAPTRapt Therapeutics-$129.87M-$19.20N/AN/AN/AN/A-81.47%-70.24%8/6/2025 (Estimated)VEGPFVectura Group$157.16M$0.266.8117.70N/AN/AN/AN/AN/ALatest OMER, VEGPF, RAPT, APRE, and EMIS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025OMEROmeros-$0.46N/AN/AN/AN/AN/A5/15/2025Q1 2025OMEROmeros-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million5/8/2025Q1 2025RAPTRapt Therapeutics-$2.48-$0.64+$1.84-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.905.90EMISEmisphere TechnologiesN/AN/AN/AOMEROmerosN/A1.161.16RAPTRapt TherapeuticsN/A21.1121.11VEGPFVectura GroupN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%EMISEmisphere TechnologiesN/AOMEROmeros48.79%RAPTRapt Therapeutics99.09%VEGPFVectura GroupN/AInsider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%EMISEmisphere Technologies72.90%OMEROmeros12.90%RAPTRapt Therapeutics2.36%VEGPFVectura GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.53 million4.78 millionNo DataEMISEmisphere Technologies6N/AN/ANot OptionableOMEROmeros21058.59 million51.04 millionOptionableRAPTRapt Therapeutics8016.54 million16.15 millionOptionableVEGPFVectura Group502604.26 millionN/ANot OptionableOMER, VEGPF, RAPT, APRE, and EMIS HeadlinesRecent News About These CompaniesPhilip Morris closes on the sale of Vectura GroupJanuary 2, 2025 | msn.comM&A News: Philip Morris (NYSE:PM) Will Sell Vectura for $198MSeptember 17, 2024 | msn.comVectura and Hikma to develop US asthma genericAugust 20, 2024 | pharmaphorum.comPEuropean Stocks See Mixed Session as U.K.'s FTSE LeadsJanuary 16, 2023 | thestreet.comVECTURA GROUP LS -,000271 (V4TA.BE)January 15, 2023 | finance.yahoo.comVectura Group PLC (V4TA.BE)January 9, 2023 | finance.yahoo.comResults for 'Vectura-Fertin Pharma'October 11, 2022 | afaqs.comAVectura Group (OTC:VEGPF), Short Interest ReportJuly 18, 2022 | benzinga.comCarlyle stays in race for VecturaAugust 27, 2021 | uk.finance.yahoo.comForm 8.3 - Form-8.3 - VECTURA GROUP PLC - 20210826August 27, 2021 | finance.yahoo.comPhilip Morris chief attacks critics as Vectura bid tests investorsAugust 20, 2021 | uk.finance.yahoo.comMarkets: FTSE inches to new post-pandemic high as Vectura takeover draws closerAugust 13, 2021 | uk.finance.yahoo.comVectura auction called off after Carlyle declines to beat Philip Morris bidAugust 10, 2021 | uk.finance.yahoo.comUPDATE 1-Vectura takeover battle could slip into auction - UK regulatorAugust 9, 2021 | finance.yahoo.comPhilip Morris, Carlyle could fight it out for UK's Vectura in auction ringAugust 9, 2021 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom3 Cloud Software Leaders Positioned for AI UpsideBy Chris Markoch | July 10, 2025View 3 Cloud Software Leaders Positioned for AI UpsideBroadcom’s Big VMware Update: A Threat to Public Cloud Giants?By Leo Miller | June 28, 2025View Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?GE Aerospace Turns Engines Into Long-Term ProfitsBy Jeffrey Neal Johnson | June 21, 2025View GE Aerospace Turns Engines Into Long-Term ProfitsOMER, VEGPF, RAPT, APRE, and EMIS Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.80 -0.08 (-4.26%) As of 07/10/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Emisphere Technologies OTCMKTS:EMIS$7.81 0.00 (0.00%) As of 12/9/2020Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Omeros NASDAQ:OMER$3.46 +0.08 (+2.37%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$3.45 -0.01 (-0.17%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Rapt Therapeutics NASDAQ:RAPT$8.62 +0.18 (+2.13%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$8.62 0.00 (-0.06%) As of 07/10/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyVectura Group OTCMKTS:VEGPF$1.77 0.00 (0.00%) As of 11/1/2021Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
